Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott’s Revised Meridia Labeling Adds Renal Precaution

This article was originally published in The Pink Sheet Daily

Executive Summary

Revised labeling for Abbott's Meridia (sibutramine) includes a precaution against using the weight-loss drug in patients with mild to moderate renal impairment or renal insufficiency

You may also be interested in...



Meridia Risk Management Program Sufficiently Addresses Safety Issues, FDA Says

Agency denies Public Citizen petition to remove Abbott’s weight loss drug Meridia (sibutramine) from the market.

Meridia Risk Management Program Sufficiently Addresses Safety Issues, FDA Says

Agency denies Public Citizen petition to remove Abbott’s weight loss drug Meridia (sibutramine) from the market.

Abbott's Meridia To Be Packaged With Patient Guide In 30-Count Bottle

The monthly supply bottles will replace existing 100-count bottles to simplify distribution of the new patient leaflet emphasizing the risk of increased blood pressure and heart rate. Meridia is the fourth of seven drugs flagged by FDA safety officer Graham to have safety information strengthened.

Related Content

Topics

UsernamePublicRestriction

Register

PS062735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel